Corbus Pharmaceuticals Holdings, Inc. Share Price
Stocks
CRBP
US21833P3010
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
09:24:00 11/11/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 4.075 USD | +3.69% |
|
+13.45% | -50.25% |
| Market Cap | 8.1Cr 7.26Cr 6.69Cr 6.08Cr 12Cr 759.3Cr 12Cr 80Cr 32Cr 406.81Cr 30Cr 30Cr 1.29TCr | P/E 2026 * |
-0.61x | P/E 2027 * | -0.71x |
|---|---|---|---|---|---|
| Enterprise Value | 8.1Cr 7.26Cr 6.69Cr 6.08Cr 12Cr 759.3Cr 12Cr 80Cr 32Cr 406.81Cr 30Cr 30Cr 1.29TCr | EV / Sales 2026 * |
56.7x | EV / Sales 2027 * | 24.5x |
| Free-Float |
92.7% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CRBP | Delayed | |
CBOE
| CRBP | Real-time | |
|
London S.E.
| 0SZI | Delayed | |
|
Tradegate
| 3371 | Real-time | |
|
Boerse Muenchen
| 3371 | Real-time | |
|
Deutsche Boerse AG
| 3371 | Delayed | |
|
Börse Stuttgart
| 3371 | Delayed |
Last Transcript: Corbus Pharmaceuticals Holdings, Inc.
| 1 day | +3.31% | ||
| 1 week | +13.45% | ||
| Current month | -4.03% | ||
| 1 month | -23.15% | ||
| 3 months | -57.41% | ||
| 6 months | -63.32% | ||
| Current year | -50.25% |
| 1 week | 2.81 |  | 4.12 |
| 1 month | 2.81 | | 5.4 |
| Current year | 2.81 | | 12.88 |
| 1 year | 2.81 | | 12.88 |
| 3 years | 2.81 | | 61.9 |
| 5 years | 2.11 | | 61.9 |
| 10 years | 2.11 | | 315 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 51 | 11/04/2014 |
Sean Moran
DFI | Director of Finance/CFO | 68 | 11/04/2014 |
Leonardo Nicacio
CTO | Chief Tech/Sci/R&D Officer | 48 | 06/07/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Yuval Cohen
BRD | Director/Board Member | 51 | 11/04/2014 |
John Jenkins
BRD | Director/Board Member | 68 | 05/06/2018 |
Rachelle Jacques
CHM | Chairman | 54 | 15/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/10/26 | Cormorant Asset Management LP
| Sell | Company | -4,25,000 | 2.1974% | |
| 14/09/26 | Sell | Director | -2,000 | 0.0103% | ||
| 16/08/26 | Free | Chief Technology Officer | 2,50,009 | 1.3494% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.69% | +13.45% | -61.13% | +28.16% | 8.1Cr | |
| -1.06% | +9.92% | +59.12% | +68.61% | 6.83TCr | |
| +0.93% | +7.02% | +14.37% | +89.57% | 6.03TCr | |
| +0.03% | +0.03% | +19.72% | +97.20% | 5.59TCr | |
| -0.91% | +11.19% | +22.23% | +111.24% | 4.84TCr | |
| +1.25% | +5.71% | +27.60% | +43.98% | 4.53TCr | |
| -4.70% | -7.49% | +188.30% | +840.15% | 4.18TCr | |
| +1.97% | +9.00% | +25.20% | +50.98% | 3.45TCr | |
| -0.61% | -0.92% | +84.73% | +57.00% | 3.38TCr | |
| -1.49% | +13.52% | +43.09% | +0.06% | 2.6TCr | |
| Average | -0.11% | +2.85% | +42.32% | +138.70% | 4TCr | |
| Weighted average by Cap. | -0.44% | +4.03% | +50.79% | +148.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 14.29L 12.81L 11.81L 10.72L 20.29L 13Cr 20.86L 1.41Cr 56.33L 7.18Cr 53.61L 52.48L 23Cr | 33L 29.59L 27.27L 24.77L 46.88L 31Cr 48.19L 3.27Cr 1.3Cr 17Cr 1.24Cr 1.21Cr 52Cr |
| Net income | -12Cr -11Cr -9.83Cr -8.93Cr -17Cr -1.12TCr -17Cr -117.72Cr -47Cr -597.58Cr -45Cr -44Cr -1.89TCr | -14Cr -13Cr -12Cr -11Cr -20Cr -1.34TCr -21Cr -141Cr -56Cr -715.72Cr -53Cr -52Cr -2.26TCr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/26/11 | $4.080 | +3.82% | 1,22,369 |
| 10/26/10 | $3.930 | +11.65% | 6,45,629 |
| 09/26/09 | $3.520 | +14.66% | 12,47,576 |
| 06/26/06 | $3.070 | +7.34% | 6,85,228 |
| 05/26/05 | $2.860 | -19.89% | 13,56,435 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CRBP Stock
Select your edition
All financial news and data tailored to specific country editions
